Monocyte subsets and their phenotypes during treatment with BCR‐ABL1 tyrosine kinase inhibitors for Philadelphia chromosome‐positive leukemia - Konuma, Takaaki; Kohara, Chisato; Watanabe, Eri; Mizukami, Motoko; Nagai, Etsuko; Tanoue, Susumu; Isobe, Masamichi; Jimbo, Koji; Kato, Seiko; Ohno, Nobuhiro; Takahashi, Satoshi; Tojo, Arinobu (Hematological oncology, 2018)
Keywords: Adult; Aged; Aged, 80 and over; BCR-ABL protein; CC chemokine receptors; CCR2 protein; chemokine receptor; Chemokine receptors; Chemokines; CX3CR1 protein; dasatinib; Dasatinib - therapeutic use; Female; Fusion Proteins, bcr-abl - antagonists & inhibitors; Humans; Imatinib; Imatinib Mesylate - therapeutic use; Inhibitors; Kinases; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism; Male; Middle Aged; monocyte; Monocyte chemoattractant protein 1; Monocytes; Monocytes - drug effects; Monocytes - metabolism; nilotinib; Patients; Phenotype; Philadelphia chromosome; Protein Kinase Inhibitors - therapeutic use; Pyrimidines - therapeutic use; Receptors; Receptors, Chemokine - metabolism; scavenger receptor; Scavenger receptors; Scavenger Receptors, Class A - metabolism; Targeted cancer therapy; Tyrosine; Tyrosine kinase inhibitors; vascular event; scavenger receptor; dasatinib; vascular event; nilotinib; imatinib; monocyte; chemokine receptor